You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

 

Online download statistics by month:

Online download statistics by month: October 2020 to March 2026

AbstractFullPdf
Oct 2020273273111
Nov 2020224224111
Dec 202010710763
Jan 202113613659
Feb 202113113142
Mar 202117517552
Apr 202111111029
May 202112412452
Jun 202112712744
Jul 202112612650
Aug 2021888833
Sep 2021828226
Oct 202110910971
Nov 202111011263
Dec 2021787939
Jan 2022757960
Feb 2022485339
Mar 2022949639
Apr 202215516446
May 202210310538
Jun 202210611330
Jul 2022748738
Aug 2022929425
Sep 2022838741
Oct 2022899139
Nov 2022727329
Dec 2022444421
Jan 2023939421
Feb 2023999927
Mar 2023979847
Apr 2023636331
May 2023626320
Jun 2023474721
Jul 2023404227
Aug 2023717123
Sep 2023353514
Oct 2023454517
Nov 2023434519
Dec 2023687020
Jan 2024363724
Feb 2024585821
Mar 2024626278
Apr 2024696928
May 2024595926
Jun 2024434321
Jul 2024434421
Aug 2024615828
Sep 2024454719
Oct 2024737328
Nov 2024707327
Dec 2024848731
Jan 2025808047
Feb 202511911922
Mar 2025575726
Apr 2025707027
May 2025879032
Jun 2025626226
Jul 2025110
Mar 2026110
Total497950512109